Cassava Sciences Gestion
Gestion contrôle des critères 3/4
Le PDG Cassava Sciences est Rick Barry, nommé en Sep2024, a un mandat de moins d'un an. détient directement 0.98% des actions de la société, d'une valeur de $ 2.02M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2 ans et 6.8 ans.
Informations clés
Rick Barry
Directeur général
US$546.2k
Rémunération totale
| Pourcentage du salaire du PDG | n/a |
| Durée du mandat du directeur général | less than a year |
| Propriété du PDG | 1.0% |
| Durée moyenne d'occupation des postes de direction | 2yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 6.8yrs |
Mises à jour récentes de la gestion
Recent updates
Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh
Nov 07Cassava Sciences: Turning The Corner Into A Brick Wall
Jul 24Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Oct 17
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Jul 04We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate
Mar 05Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Nov 19Cassava Sciences begins extension study of Alzheimer's drug simufilam
Oct 13Cassava Sciences Stock: Huge Returns Or Catastrophic Losses
Sep 29Cassava Sciences: Trying To Manage Expectations
Sep 21Cassava Sciences reaches over five-month high on rising volumes
Sep 09Cassava Sciences Looks As Good Of A Purchase As Ever
Sep 03Cassava Sciences stock jumps 10% after director buys $860K shares
Aug 26Cassava Sciences rally continues as stock up 39%
Aug 17Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results
Aug 11Cassava Sciences GAAP EPS of -$0.48 misses by $0.06
Aug 03We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Aug 03Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug
Jul 27Cassava Sciences And Alzheimer's Disease: A Precipitious Path
Jun 10Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate
May 31Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait
Apr 193 Key Points To Remember About Cassava Sciences
Apr 07Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences
Mar 31Cassava Sciences: Why The Stock Is Rangebound
Feb 28The FDA Deals Another Blow To Cassava Sciences' Bears
Feb 11Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity
Feb 02INmune Bio, The Biotech In My Stable For After Cassava Sciences
Jan 17Cassava Sciences, Inc. - The Short Squeeze Has Started
Jan 06Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam
Dec 30Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
Dec 28Cassava Sciences Stock: Here We Go Again
Dec 21Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing
Dec 02PDG
Rick Barry (65 yo)
less than a year
Titularisation
US$546,155
Compensation
Mr. Richard Jon Barry, also known as Rick, served as Independent Director at Cassava Sciences, Inc. since June 11, 2021, until July 17, 2024 and serves as its Executive Chairman of the Board since July 17,...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$546.16k | 0.98% $ 2.0m | |
| Chief Financial Officer | 6.1yrs | US$2.99m | 0.048% $ 100.1k | |
| Senior VP | 2.1yrs | US$1.27m | 0% $ 0 | |
| Chief Medical Officer | 3.8yrs | US$2.97m | 0.0083% $ 17.2k | |
| Senior Vice President of Technology | no data | pas de données | pas de données | |
| Senior Vice President of Technical Operations | no data | pas de données | pas de données | |
| Senior Vice President of Regulatory Affairs | 2yrs | pas de données | pas de données | |
| Senior Vice President of Neuroscience | 4.6yrs | pas de données | pas de données | |
| Chief Commercial Officer | no data | pas de données | pas de données | |
| Chief Clinical Development Officer | no data | pas de données | pas de données |
2.0yrs
Durée moyenne de l'emploi
62.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de SAVA est considérée comme expérimentée (ancienneté moyenne 2 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 3.4yrs | US$546.16k | 0.98% $ 2.0m | |
| Independent Director | 16.9yrs | US$438.42k | 0.0025% $ 5.1k | |
| Independent Director | 26.4yrs | US$438.42k | 0.017% $ 35.4k | |
| Member of Scientific Advisory Board | 10.1yrs | US$558.31k | pas de données | |
| Independent Director | 21.7yrs | US$546.16k | 0.026% $ 54.7k | |
| Independent Chairman | less than a year | US$474.50k | 0% $ 0 | |
| Independent Director | less than a year | US$474.50k | 0% $ 0 | |
| Independent Director | less than a year | US$474.50k | 0% $ 0 |
6.8yrs
Durée moyenne de l'emploi
68.5yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de SAVA sont considérés comme expérimentés (ancienneté moyenne 6.8 ans).